Does melatonin help save dopaminergic cells in MPTP-treated mice?

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Parkinson disease is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc).
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that induces Parkinsonism in animal models, causing SNc cell death.

Purpose of the Study:

• To investigate the neuroprotective potential of melatonin against MPTP-induced dopaminergic cell degeneration in the SNc.
• To evaluate the efficacy of melatonin pre-treatment in preserving SNc neurons in a mouse model of Parkinson disease.

Main Methods:

• BALB/c albino mice were divided into four groups: Saline, Melatonin (Mel), MPTP, and Melatonin-MPTP (Mel-MPTP).
• Mice received intraperitoneal injections of saline, melatonin, or MPTP in various combinations.
• Brains were analyzed six days post-injection using tyrosine hydroxylase (TH) immunochemistry and Nissl staining with unbiased stereology.

Main Results:

• The Mel-MPTP group exhibited significantly higher numbers of TH-positive cells (50% increase) and Nissl-stained cells (30% increase) in the SNc compared to the MPTP-only group.
• No significant difference was observed in SNc cell counts between the Mel-MPTP group and the control groups (Saline and Mel).
• These findings demonstrate a neuroprotective effect of melatonin against MPTP-induced neurodegeneration.

Conclusions:

• Melatonin pre-treatment effectively protects dopaminergic neurons in the SNc from MPTP-induced toxicity.
• Melatonin shows potential as a therapeutic agent for preventing or mitigating neurodegeneration in Parkinson disease models.